{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:20:37Z","timestamp":1783034437098,"version":"3.54.6"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Startup Fund for scientific research, Fujian Medical University","award":["2023QH1301"],"award-info":[{"award-number":["2023QH1301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51364-7","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T16:17:22Z","timestamp":1777738642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world chemotherapy use and survival outcomes in postmenopausal HR+\/HER2\u2212breast cancer with low genomic risk (RS\u2009\u2264\u200925): a multicenter cohort study from China"],"prefix":"10.1038","volume":"16","author":[{"given":"Chengye","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duanduan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"51364_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151547","volume":"40","author":"J Gilchrist","year":"2024","unstructured":"Gilchrist, J. Current management and future perspectives of hormone receptor-positive Her2-negative advanced breast cancer. Semin. Oncol. Nurs. 40, 151547 (2024).","journal-title":"Semin. Oncol. Nurs."},{"key":"51364_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer. N. Engl. J. Med. 379, 111\u2013121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"51364_CR3","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik, S. et al. A multigene assay to predict recurrence of Tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817\u20132826 (2004).","journal-title":"N. Engl. J. Med."},{"key":"51364_CR4","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik, S. et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24, 3726\u20133734 (2006).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"51364_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky, K. et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med. 385, 2336\u20132347 (2021).","journal-title":"N. Engl. J. Med."},{"key":"51364_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s10549-025-07661-2","volume":"211","author":"R Han","year":"2025","unstructured":"Han, R. et al. Oncotype Dx recurrence score in node-positive patients in the post-Rxponder era: A single-institution experience. Breast Cancer Res. Treat. 211, 449\u2013454 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"51364_CR7","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-024-07486-5","volume":"209","author":"IM Browne","year":"2025","unstructured":"Browne, I. M. et al. Irish national real-world analysis of the clinical and economic impact of 21-gene oncotype Dx(R) testing in early-stage, 1\u20133 lymph node-positive, oestrogen receptor-positive, her2-negative. Breast Cancer. Breast Cancer Res. Treat. 209, 189\u2013199 (2025).","journal-title":"Breast Cancer. Breast Cancer Res. Treat."},{"key":"51364_CR8","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/oncolo\/oyac123","volume":"27","author":"S Hassan","year":"2022","unstructured":"Hassan, S. et al. Impact of the 21-gene recurrence score assay on treatment decisions and cost in patients with node-positive breast cancer: A multicenter study in Quebec. Oncologist. 27, 822\u2013831 (2022).","journal-title":"Oncologist."},{"key":"51364_CR9","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1016\/j.clbc.2021.09.004","volume":"22","author":"N LeVasseur","year":"2022","unstructured":"LeVasseur, N. et al. Impact of the 21-Gene recurrence score assay on the treatment of estrogen receptor-positive, Her2-negative, breast cancer patients with 1-3 positive nodes: A prospective clinical utility study. Clin. Breast Cancer. 22, e74\u2013e79 (2022).","journal-title":"Clin. Breast Cancer."},{"key":"51364_CR10","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41416-020-01247-z","volume":"124","author":"RP Giorgi","year":"2021","unstructured":"Giorgi, R. P. et al. Recommendations from the European Commission initiative on breast cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, her-2 negative. Br. J. Cancer. 124, 1503\u20131512 (2021).","journal-title":"Br. J. Cancer."},{"key":"51364_CR11","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1200\/JCO.22.00069","volume":"40","author":"F Andre","year":"2022","unstructured":"Andre, F. et al. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J. Clin. Oncol. 40, 1816\u20131837 (2022).","journal-title":"J. Clin. Oncol."},{"key":"51364_CR12","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41416-024-02588-9","volume":"130","author":"S Holt","year":"2024","unstructured":"Holt, S. et al. A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with Node+Ve, Hormone Receptor+Ve, HER2-Ve breast cancer. Br. J. Cancer. 130, 1149\u20131156 (2024).","journal-title":"Br. J. Cancer."},{"key":"51364_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.36469\/jheor.2025.137277","volume":"12","author":"H Loponen","year":"2025","unstructured":"Loponen, H. et al. Size and treatment outcomes of Hr+, Her2- Early breast cancer population with high risk of recurrence: A real-world cohort study with Danish breast cancer cooperative group registry data. J. Health Econ. Outcomes Res. 12, 252\u2013260 (2025).","journal-title":"J. Health Econ. Outcomes Res."},{"key":"51364_CR14","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3892\/ol.2020.11734","volume":"20","author":"J Yu","year":"2020","unstructured":"Yu, J. et al. Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30. Oncol. Lett. 20, 1545\u20131556 (2020).","journal-title":"Oncol. Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51364-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T22:58:01Z","timestamp":1783033081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51364-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51364"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51364-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"14 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Ethics Committee of Quanzhou First Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Formal consent was not required for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"20401"}}